Tanshinone IIA promotes the differentiation of bone marrow mesenchymal stem cells into neuronal-like cells in a spinal cord injury model
- 512 Downloads
Spinal cord injury (SCI) is one of the most severe central nervous system injuries. Currently, transplanting bone marrow mesenchymal stem cells (BMSCs) is considered a therapeutic option for SCI. Tanshinone IIA (TIIA) is one of the extracts obtained from Salvia miltiorrhiza Bunge, which has been shown to have some protective effects against SCI. The present research was aimed to explore whether TIIA would influence the fate of transplanted BMSCs in a rat model of SCI, especially with regard to their differentiation into neuronal cells.
Bone marrow mesenchymal stem cells were obtained from immature rats and identified using flow cytometry. After SCI, 1.0 × 107 cells labeled with PKH67 were transfused into the injured spinal cord. TIIA was first injected into the tail vein (30 mg/kg) 1 h before surgery. From day 1 to day 7 post-SCI, TIIA was injected (20 mg/kg) per day at the same time. Recovery of locomotor function and histological regeneration of the spinal cord were compared among the groups, with the differentiation and distribution of BMSCs determined anatomically and biochemically by the expression of neural cell markers.
Locomotor assessments showed that the rats in the BMSCs + TIIA group exhibited higher scores (19.33 ± 0.58) than those in the other groups (13.67 ± 1.53, 17.67 ± 0.58, 18.00 ± 1.73). The area of the cavity in the BMSCs + TIIA rats was smaller than that in the other groups (1.30 ± 0.56, 10.39 ± 1.59, 6.84 ± 1.18, 4.36 ± 0.69). Co-expression of glial fibrillary acid protein was observed in transplanted BMSCs, with a reduced rate in the BMSCs + TIIA group relative to that in the SCI group. In contrast, the expression levels of Nestin, neuron-specific nuclear protein (NeuN) and neurofilament protein 200 (NF200) were greatest in the transplanted cells in the BMSCs + TIIA group.
Tanshinone IIA treatment enhances the therapeutic effects of BMSC transplant on SCI, likely by promoting the differentiation of neuronal cells.
KeywordsSpinal cord injury Tanshinone IIA Bone marrow mesenchymal stem cells Differentiation
spinal cord injury
central nervous system
bone marrow mesenchymal stem cells
Salvia Miltiorrhiza Bunge
glial fibrillary acid protein
neurofilament protein 200
Basso, Beattie, Bresnahan
hematoxylin and eosin
Dulbecco’s modified Eagle’s medium F12
heat-inactivated fetal bovine serum
sodium dodecyl sulfate
Spinal cord injury (SCI) is one of the most severe central nervous system (CNS) lesions that affects a patient’s physical and mental health, has a heavy economic burden on society and detrimentally affects the patient’s family . There currently is no effective treatment strategy for SCI in clinical practice, with treatment opinions entailing the use of high dose methylprednisolone, surgical interventions to stabilize and decompress the spinal cord, and rehabilitative care. However, cellular, molecular, or rehabilitative training with combinatorial therapies are beginning to show promising results in animal models . Among the potential drugs that may be helpful for SCI is Salvia miltiorrhiza Bunge (SMB), a traditional Chinese herb that is currently used for the treatment of various diseases, in particular cardiovascular and cerebrovascular cases [3, 4]. Tanshinone I, tanshinone IIA (TIIA) and cryptotanshinone are the three major bioactive diterpenoid quinones isolated from SMB . TIIA is the most abundant diterpene quinone, which has potential protective effects against atherosclerosis, cardiac hypertrophy, cardiac fibrosis, also can attenuate oxidative stress induced apoptosis . Thus it recently has been used in treating cardiovascular diseases, specifically hypertension and myocardial infarction . It also appears to have a protective effect against SCI by inhibiting proinflammatory processes and SCI-induced apoptosis [7, 8].
With the development of cell and molecular biology, the transplantation of stem cells has been considered a promising therapeutic treatment . Recently, bone marrow mesenchymal stem cells (BMSCs) have received much attention since they are easily isolated and cultured, and they exhibit a favorable proliferative profile, an ability for polydirectional differentiation and a reduced immunological reaction. In view of these prospects, BMSCs have been used as a therapy for orthopedic, cardiovascular and neurological diseases [10, 11, 12, 13]. Our previous data demonstrate that BMSCs can improve function in a cerebral ischemia model , and BMSCs have been used in the clinic for the treatment of SCI . In recent years, scientists have proven that TIIA could increase BMSCs migration into the infarct region in a myocardial ischemia model [16, 17]. However, there is no data on the combined therapeutic effect of TIIA treatment with stem cells transplantation on SCI. The aim of the current study was to investigate whether TIIA could promote differentiation of BMSCs into neurocyte-like cells in an SCI model and subsequently improve behavioral outcome and morphology.
Rabbit monoclonal antibody
IHC (1:400) IF (1:200) WB (1:2000)
Mouse monoclonal antibody
IHC (1:200) IF (1:200) WB (1:2000)
Mouse monoclonal antibody
IHC (1:200) IF (1:200) WB (1:10,000)
Mouse monoclonal antibody
IHC (1:100) IF (1:200) WB (1:10,000)
Sprague-Dawley (SD) female adult rats (7 weeks old, weighing 200–220 g) were purchased from the animal center of the Second Affiliated Hospital of Harbin Medical University. The rats were housed at room temperature (25 °C) and were provided a standard laboratory diet and water ad libitum.
Spinal cord injury
Rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (3 mL/kg). Under aseptic conditions, hair was removed from the T8–T11 region of the back, the skin was sterilized with antiseptic betadine, and then a 2-cm midline incision was made. The spinal cord was exposed by laminectomy at the T9–T10 level, without damaging the dura mater. An SCI was generated by using an aneurysm clip exerting a 0.6-N closing force on the spinal cord for 1 min . Subsequently, muscle and skin were sutured with 3-0 Vicryl suture. Post-operatively, gentamicin was added into the water at a dose of 500 g/L for 7 days to prevent infection. Body temperature was kept at 37 °C by using a warm blanket during surgery and the post-operative recovery period. Two rats without hindlimb paralysis post-surgery were excluded from this study. Urine was manually cleared from rats post-operatively twice daily (i.e., for 7–14 days) by pressing the bladder until the rats could urinate by themselves.
A total of 56 rats were used in this study, eight were sacrificed for gross findings and electron microscopy analysis. The other 48 SCI rats were randomly assigned to four groups. (1) Group A was the control group (SCI only, n = 12); (2) Group B was the TIIA group (injection of TIIA, n = 12); (3) Group C was the BMSCs group (transplantation of BMSCs, n = 12); (4) Group D was the BMSCs + TIIA group (transplantation of BMSCs and injection of TIIA, n = 12; Sup. 1). The chemically pure TIIA were purchased from Klamar reagent company (Cas. No. 568729). The TIIA’s purity is more than 98% and has no immunogenicity, so it is used safely in our experiments. TIIA was initially injected 1 h before surgery via the tail vein (30 mg/kg) and then on days 1–7 post-SCI, and TIIA (20 mg/kg) was administered once a day at the same time [16, 19]. BMSCs (1.0 mL containing 1.0 × 107 cells/mL) were intravenously transplanted 3 h after SCI. Before transplantation, BMSCs were labeled with PKH67 to assess their localization later. Control rats received the same volume of a 0.9% sterile saline solution via the tail vein. An open field locomotor assessment was performed on all animals using the Basso, Beattie, Bresnahan (BBB) scale at 1, 7, 14, 21, and 28 days post-surgery. On the first day post-surgery, one SCI rat and one normal control rat were sacrificed and the injured region of spinal cord was collected for gross findings. At 2 days post-SCI, the spinal cords from three SCI rats and three normal rats were collected for electron microscopy analysis. The remaining animals were sacrificed at 28 days post-SCI for H&E (hematoxylin and eosin) staining, immunohistochemistry, triple immunofluorescent staining, western blotting and real-time PCR analysis.
Isolation, culture and differentiation of BMSCs
Rat BMSCs were isolated using a density gradient centrifugation method and were then cultured according to a protocol previously described . Eight SD male rats (4 weeks old) were deeply anesthetized with an overdose of 10% chloral hydrate. Bone marrow was flushed out from the femoral and shin bones using 4.0 mL of Dulbecco’s modified Eagle’s medium F12 (DMEM/F12, HyClone) under aseptic conditions. Bone marrow was then added to an equal volume of rat lymphocyte separation medium (density: 1.083 g/mL, Solarbio, China) in a 15.0-mL plastic centrifuge tube and centrifuged at 2500 rpm for 30 min (centrifugal radius = 20 cm) with bone marrow mononuclear cells harvested from the second layer (from top to bottom). The collected cells were washed in DMEM/F12 and resuspended in T25 culture flasks with DMEM/F12 supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sciencell, USA), 100 U/mL penicillin and 0.1 mg/mL streptomycin (Beyotime, China). The bone marrow mononuclear cells were then plated at a density of 5.0 × 106 cells per flask and incubated in a humidified atmosphere of 5% CO2/95% O2 at 37 °C. Three days later, the non-adherent cells were removed and then added to fresh culture medium; the medium was changed every 2–3 days. When cells reached 80–90% confluence, they were digested with 0.25% trypsin and 0.02% EDTA (Beyotime, China) and subcultured. Cells were cultured for three passages for identification, labeling and transplantation. Adipogenesis was induced by using the OriCell™ adipogenic differentiation kit (Cyagen, Guangzhou, China). The OriCell™ osteogenesis differentiation kit (Cyagen, Guangzhou, China) was used to induce osteogenic differentiation. The capacity of the BMSCs for differentiation to adipogenic and osteogenic cells was assessed as described previously .
Identification and labeling of BMSCs
Flow cytometric analysis was performed to identify the cellular surface phenotype of cultured cells. BMSCs were treated with trypsin–EDTA solution and then washed three times with PBS containing 10% bovine serum albumin (BSA; Beyotime). The cells then were added and incubated with primary monoclonal rat antibodies including phycoerythrin (PE)-conjugated CD29, allophycocyanin (APC)-conjugated CD90, fluorescein isothiocyanate (FITC)-conjugated CD45, purified CD73, purified CD34 and CD44 for 30 min at 4 °C. The secondary antibodies included PE-conjugated rat anti-mouse IgG1 and FITC-conjugated goat anti-rabbit IgG H&L. The isotype-matched controls included mouse G1-PE, mouse G1-APC, mouse G1-FITC, hamster IgM-PE, and rabbit IgG (Abcam, USA). Labeled cells were analyzed by a FACS Calibur flow cytometer (Becton–Dickinson) using Cell Quest software.
Before transplantation, the BMSCs were labeled with the fluorescent membrane dye PKH67 (green fluorescence dye, Sigma). PKH67 is recommended for short-to-medium term in vivo studies that require a green cell linker dye, as well as in vitro cytotoxicity, proliferation or other co-culture assays [22, 23]. After surgery, 1.0 × 107 cells labeled with PKH67 (the BMSCs and BMSCs + TIIA groups) were resuspended in 1.0 mL of 0.9% sterile saline solution and injected slowly through the tail vein over 5 min .
Locomotor activity test
The recovery of locomotor function was assessed using the BBB scale . The BBB 21-point open field locomotor rating scale (0 = complete paralysis, 21 = normal gait) was performed at 1, 7, 14, 21, and 28 days after surgery to evaluate hindlimb movement. Animals were placed individually in a circular enclosure and allowed to move freely for 5 min. Two independent examiners who were blinded to the treatment groups monitored the animals’ behaviors, recorded their scores and calculated the average score.
Histopathology and electron microscopy analysis
The other three SCI rats and three normal rats were sacrificed at 2 days post-SCI, and the spinal cord sections 1.0 cm rostral to 1.0 cm caudal to the injury site were removed and fixed in 3.6% glutaraldehyde containing 0.1 M phosphate buffer for 15 min. A 1-mm slice was cut transversely at the lesion epicenter, fixed in buffered osmium tetroxide, dehydrated in cold graded ethanol and embedded in Epon Araldite (Electron Microscopy Sciences, Fort Washington, PA). Sagittal sections (1.0 μm) were stained with 1% toluidine blue. A plastic-embedded cross-section of spinal cord was divided into thirds, and these areas were carefully mapped before thin sectioning. Thin sections were stained with uranyl acetate and lead citrate and examined with an electron microscope (JEM-1400, JEOL Ltd., Tokyo, Japan) operating at 80 kV .
Immunohistochemistry and immunofluorescence
Rats were sacrificed was at 28 days (n = 24) post-surgery. The tissues for immunofluorescence were immersed in 30% sucrose until they sank. The spinal cord was cut transversely using a cryostat at a thickness of 20.0 μm with sections mounted on frosted glass slides and stored at − 20 °C until use. Primary monoclonal rat antibodies included rabbit anti-GFAP, mouse anti-Nestin, mouse anti-NeuN, and mouse anti-NF200.
For immunohistochemistry using the avidin–biotin-complex (ABC) method, sections were first treated with 3% H2O2 for 30 min; blocked in PBS containing 10% goat serum, 0.2% Triton X-100 and 5% BSA for 1 h at room temperature; and then were reacted with primary antibodies (for GFAP, Nestin, NeuN, and NF200) overnight. The next day, sections were incubated with biotinylated pan-specific secondary antibodies (goat anti-mouse IgG, goat anti-rabbit IgG, Boster, China) at 1:200 for 2 h, followed by the ABC step (1:400, Boster, China) for 1 h. Immunoreactivity was visualized using 0.05% 3,3′-diaminobenzidine (DAB) and 0.003% H2O2.
To assess the survival, migration, and proliferation of PKH67-labeled BMSCs, an immunofluorescence triple staining protocol was performed using a previously described procedure. Briefly, after washing sections with PBS, they were incubated in Alexa-Flour 594 conjugated goat anti-rabbit and mouse IgG (1:100, MultiSciences, China) for 1 h. Finally, sections were counterstained with 4′, 6′-diamino-2- phenylindole (DAPI) dihydrochloride (1:100, Boster, China) and mounted with anti-fading medium before images were acquired.
Signals were detected and imaged using an Olympus microscope (BX41, Olympus, Japan) and confocal fluorescence microscope (FV-1000 spectral, Olympus, Japan) at 535 nm/565 nm (rhodamine, red) and 470 nm/505 nm (FITC, green) using a digital camera. The numbers of positive cells were determined by averaging the numbers of cells counted in six randomly selected areas of three non-consecutive sections in each group and calculated using the ImageJ and FLUOVIEW in the confocal microscope system (×200, ×400).
Animals were deeply anesthetized with an overdose of 10% chloral hydrate at 28 days post-surgery. The lesioned spinal cords (2.0 cm in length) were extracted and stored at − 80 °C. The tissue was then homogenized on ice in radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 50 mM Tris–HCl pH 7.4, 2 mM EDTA, 1% NP-40, 0.1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM Na3VO4, 1 mM sodium deoxycholate, 1 mM PMSF, 10 mg/mL aprotinin, and 5 mg/mL leupeptin) and centrifuged at 12,000 rpm for 20 min at 4 °C. The supernatant (50 μg of total protein) was separated on 10% SDS gels (Beyotime) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 10% non-fat milk in TBST (25 mM Tris–HCl, 0.15 mM NaCl, 0.1% Tween 20) for 1 h, the PVDF membranes were incubated at 4 °C overnight with primary antibodies: rabbit anti-GFAP (1:2000, Abcam, USA), mouse anti-Nestin (1:1000, Abcam, USA), mouse anti-NeuN (1:5000, Abcam, USA), mouse anti-NF200 (1:2000, Abcam, USA) and β-actin (1:500, ZSGB Biological, China). After washing with PBS containing 0.1% Tween 20, the membranes were incubated with appropriate secondary antibodies: horseradish peroxidase-labeled goat anti-rabbit IgG and goat anti-mouse IgG (1:5000, ZSGB Biological, China) for 2 h. Finally, membranes were washed again, and the bands were detected with an enhanced chemiluminescence (ECL) detection kit (Beyotime, China) and exposed to X-ray films. Western blotting bands were quantified using Quantity One software.
Real-time PCR analysis
Primers used for PCR analysis
Primer sequence (5′-3′)
The data are presented as the means ± SDs and were analyzed using GraphPad Prism 5.0 software (GraphPad, La Jolla, CA, USA) and ImageJ. A one-way analysis of variance (ANOVA) and Student’s t test (paired) were used to compare multiple groups and two groups, respectively. Analysis of the BBB scale data was performed by two-way ANOVA of repeated measures. A value of P < 0.05 was used to deem statistical significance.
Histological and microscopic changes after SCI
To compare the extent of SCI, we assessed the histological changes at the epicenter of the lesion using gross examination at 1 day after SCI and microscopic examination via light microscopy at 28 days post-surgery. Compared with the normal non-lesioned spinal cord tissue, the injured cord exhibited tissue with a mechanical insult that included edema and loose tissue structures (Fig. 1A). At 28 days after SCI, the cavity formations were examined in all groups (Fig. 1C1–F2). The percentage of cavity formations areas in the transverse section at the epicenter of the injured spinal cord in the sham, SCI, TIIA, BMSCs, and BMSCs + TIIA groups were 0.54 ± 0.30, 10.39 ± 1.59, 6.84 ± 1.18, 4.36 ± 0.69, and 1.30 ± 0.56, respectively. There was no significant difference between the sham and BMSCs + TIIA groups, while there were significant differences among the other groups (i.e., SCI vs TIIA, SCI vs BMSCs, SCI vs BMSCs + TIIA, TIIA vs BMSCs, TIIA vs BMSCs + TIIA, BMSCs vs BMSCs + TIIA, ***P < 0.001; Fig. 1g).
Characteristics of cultured BMSCs
Engraftment and differentiation of BMSCs in the injured spinal cord
Protein levels of glial and neuronal cell markers
Real-time PCR for glial and neuronal gene expressions
GFAP, Nestin, NeuN, and NF200 gene expression were examined using real-time PCR on tissue harvested at 28 days post-surgery (Fig. 6e). The expression of GFAP in the SCI group was higher relative to that in the other three groups (n = 3, *P < 0.05), while the expression levels of Nestin, NeuN, and NF200 were significantly greater in the BMSCs + TIIA group compared to those in the SCI group (n = 3, *P < 0.05, **P < 0.01). Moreover, the expression of GFAP in the BMSCs + TIIA group was significantly lower than that observed in the SCI group (n = 3, **P < 0.01).
Recovery of locomotor function
In SCI studies, there are in generally three main classes of rodent injury models: transection, contusion and compression. However, most humans suffer from an acute impact injury followed by a period of compression sometime later in their life. Therefore, many researchers use the ‘dura-intact’ compression and contusion injury model . To simulate the events of SCI in this study, we used a modified aneurysm clip to squeeze the spinal cord without damaging the dura  and then examined the effects of TIIA’s treatment on BMSCs engraftment and differentiation.
Assessment of the SCI in our model entailed examining the extent of bilateral hindlimb movement and was considered successful if the rat’s hindlimbs were totally paralytic based on the BBB scale . This scale was also used to assess locomotor outcomes post-treatment since this scale is sensitive and very reliable. Further, we assessed successful SCI by examining gross anatomical features, as well as cellular features via electron microscopy and H&E staining, which revealed edema and loose tissue structures in our model . Trauma to the spinal cord leads to immediate mechanical damage and a cascade of secondary damage . The secondary damage develops within from minutes to hours following initial mechanical damage, including the infiltration of inflammatory cells, the destruction of neuronal and glial cells, neuronal death, oxidative stress and locomotor dysfunction. In our study, there were no notably differences in secondary damage among the different groups.
To investigate the migration and proliferation of transplanted BMSCs into the lesioned spinal cord, engrafted BMSCs were prelabeled with a fluorescent membrane-intercalating dye, PKH67. Previous reports have shown that this fluorescent dye is ideal for in vivo cell tracking and cell proliferation studies . In this current study, PKH67-labeled BMSCs migrated toward the lesion in the spinal cord by 28 days post-BMSCs transplantation with very few labeled cells detected in other regions (image not presented). This demonstrated that transplanted BMSCs by an intravenous injection were effectively delivered to the lesion without dispersion to uninjured sections.
Although transplanted BMSCs can migrate to the site of injury, BMSCs are capable of differentiating into mature neurons or glial cells . The present study confirmed that the engrafted BMSCs could be induced to differentiate into neuronal-like and glial-like cells. Despite the ability of astrocytes to secrete neurotrophic factors and limit the pervasion of inflammatory reactions, extensive glial scarring within the lesioned area is inhibitory to axonal regrowth  and thus can perturb repair and behavioral outcomes. Neuronal-like cells can presumably replace missing or damaged neurons, modulate immune responses and facilitate tissue regeneration, thus improving the neurological deficits following an SCI.
To assess BMSC differentiation into glial-like cells, GFAP was used as an astrocytic marker. GFAP is an intermediate filament protein primarily found in astroglia that is often used as a marker for the activation of astrocytes following an injury such as SCI. As noted above, such activated astrocytes can lead to scar formation which is believed to inhibit neural regeneration . In this study, we examined whether the combined treatment of BMSCs with TIIA could potentially improve SCI outcomes by attenuating of BMSC differentiation into astrocytes. The rationale for this is based on the observations that not only can TIIA significantly promote BMSCs migration and recruitment by the up-regulation of CXCR4 in a myocardial ischemia model [16, 17] but also that in the SCI model, TIIA administration can effectively attenuate the inflammatory response, apparently resulting in a decreased number of activated astrocytes and decreased glial scar formation . Our data support these findings since TIIA treatment decreased the number PKH67-labeled cells that exhibited GFAP colocalization, and the protein level and gene expression of GFAP were decreased, as was glial scar formation. The present study reported a novel approach to optimize BMSC engraftment efficiency and increase its therapeutic effects based on the combination with TIIA in an SCI model. TIIA appears to improve BMSC engraftment and favor the differentiation of BMSCs into non-astrocytic cells.
To examine whether TIIA affected BMSC differentiation into neuronal cells, we examined the expression of three neuronal markers in PKH67-labeled engrafted BMSCs: Nestin, NeuN and NF200. Nestin is a type VI intermediate filament protein which is found in neural stem cells and can also be expressed in bone marrow stromal cells . NeuN is observed in most neuronal cell types throughout the nervous system and first appears at a developmental time point that corresponds to the initiation of neuronal terminal differentiation . NF200 is a 200-kDa neurofilament protein that appears to be an axonal marker . According to many previous reports, these three proteins are all markers of neuronal differentiation and neural regeneration and play important roles in injured spinal cord tissue, so we used them to detect the effect of TIIA on the migration and differentiation of BMSCs. In our study, we found that the BMSCs + TIIA group exhibited more PKH67-labeled cells colocalized with neuronal markers by immunohistochemistry; higher expression levels of neuronal markers versus those in the other groups by western blot and real-time PCR at 28 days post-treatment; and Nestin+, NeuN+, or NF200+ cells preferentially located at the site of the lesion. According to prior reports, TIIA can also rescue impaired neurons, enhance neuronal regeneration  and attenuate edema and blood–brain barrier disruption . Therefore, greater differentiation of BMSCs, more neural regeneration and less scar formation in the BMSCs + TIIA group in this study demonstrated that combination therapy of TIIA and BMSCs could promote BMSCs migration to the lesion and differentiation to neuronal-like cells. We also assessed the behavioral outcome of TIIA and BMSCs treatment in the SCI model. Based on the BBB scale, although there were no significant differences among the TIIA, BMSC and BMSCs + TIIA groups, we observed a faster functional recovery in the combination group compared with that in the control group and that in the groups treated with TIIA or BMSCs alone. Collectively, we demonstrated that TIIA promoted the differentiation of BMSCs into neurocyte-like cells in SCI rats and that this is concomitant with improved behavioral outcome.
One limitation of our current study is that we demonstrated this phenomenon without explaining the underlying mechanism(s). We speculate that TIIA may increase survival rates of transplanted BMSCs, increase the levels of trophic factors that BMSCs secrete into the lesion area, and reduce inflammatory cytokines. However, in order to understand the detailed mechanisms of the beneficial effects of TIIA, further experiments examining whether the combination of TIIA and BMSCs can also modulate secondary damage is required.
The present study demonstrated that TIIA could promote the differentiation of transplanted BMSCs into neurocyte-like cells in an SCI model. Thus, TIIA treatment in combination with BMSCs transplantation may be a new therapeutic approach for SCI in clinical practice.
XMZ, JM, and JF mainly contributed to the design of the work, interpreted the data, wrote and revised the manuscript. YS, BQY, MYY and JYL mainly performed the cell culture and animal experiments. ZMJ and DW analyzed all the data in the experiments. All authors read and approved the final manuscript.
The authors thank Mr. Peter R. Patrylo for his helpful advice.
The authors declare that they have no competing interests.
Availability of data and materials
The primary data supporting the conclusions of this article are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
The Medical Ethics Review Committee of Harbin Medical University approved all experiments in accordance with the Detailed Rules for Medical Research Purpose issued by the Ministry of Health, China (No. HMUIRB20150029).
This study was financially supported by the Third Batch Outstanding Youth Training Funds of Academician Wei-han Yu from Harbin Medical University.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 8.Koushki D, Latifi S, Norouzi Javidan A, Matin M. Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: a meta-analysis. J Spinal Cord Med. 2015;38:13–22.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Zhang XM, Du F, Yang D, Yu CJ, Huang XN, Liu W, Fu J. Transplanted bone marrow stem cells relocate to infarct penumbra and co-express endogenous proliferative and immature neuronal markers in a mouse model of ischemic cerebral stroke. BMC Neurosci. 2010;11:138.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Tong Y, Xu W, Han H, Chen Y, Yang J, Qiao H, Hong D, Wu Y, Zhou C. Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model. Phytomedicine. 2011;18:443–50.CrossRefPubMedGoogle Scholar
- 18.Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA. 2002;9:9450–5.CrossRefGoogle Scholar
- 23.Ledgerwood LG, Lai G, Zhang N, Garin A, Esses SJ, Ginhoux F, Merad M, Peche H, Lira SA, Ding Y, Yang Y, He X, Schuchman EH, Allende ML, Ochando JC, Bromberg JS. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol. 2008;9:42–53.CrossRefPubMedGoogle Scholar
- 24.Morita T, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Oka S, Oshigiri T, Takebayashi T, Yamashita T, Kocsis JD, Honmou O. Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience. 2016;335:221–31.CrossRefPubMedGoogle Scholar
- 40.Shen JL, Chen YS, Lin JY, Tien YC, Peng WH, Kuo CH, Tzang BS, Wang HL, Tsai FJ, Chou MC, Huang CY, Lin CC. Neuron regeneration and proliferation effects of danshen and tashinone IIA. Evid Based Complement Altern Med. 2011;2011:378907.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.